Impax Laboratories (IPXL) Cash Flow Statement

Click line-items for a historical chart and %

Net income
Depreciation and amortization	63.1M
Amortization of Credit Agreement deferred financing costs
Accretion of interest income on short-term investments
Deferred income taxes
Provision for uncertain tax positions
Tax benefit related to the exercise of employee stock options	-507K
Deferred revenue
Deferred product manufacturing costs
Recognition of deferred revenue
Amortization of deferred product manufacturing costs
Accrued profit sharing and royalty expense
Payments of profit sharing and royalty expense
Payments of accrued litigation settlements
Share-based compensation expense	23.38M
Bad debt expense	48.04M
Accounts receivable	36.82M
Inventory	-50.52M
Prepaid expenses and other assets	-42.66M
Accounts payable, accrued expenses and income taxes payable
Other liabilities	2.28M
Net cash (used in) provided by operating activities	97.77M
Purchase of short-term investments
Maturities of short-term investments	0
Purchases of property, plant and equipment	-31.86M
Net cash provided by (used in) investing activities	-604.81M
Tax benefit related to the exercise of employee stock options	507K
Proceeds from exercise of stock options and ESPP
Net cash provided by financing activities	397.78M
Net increase in cash and cash equivalents	-108.23M
Cash and cash equivalents, beginning of period	340.35M
Cash and cash equivalents, end of period	232.12M
Cash paid for interest	8.21M
Cash paid for income taxes

Entities mentioned with IPXL

View All Entities